Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and Nesa Nourmohammadi (...
Roche pharma chief Pascal Soriot's departure for AstraZeneca triggered a bit of musical chairs at the Swiss drugmaker.
AstraZeneca turned heads today with an unexpectedly intriguing CEO choice: Roche's Pascal Soriot, who's been the Swiss drugmaker's COO and pharma chief since 2010. Within hours, Soriot had a full wardrobe of expectations to try on.
In many ways, Roche is everything that AstraZeneca is not but desperately wants to be--inventive, focused, with a reputation for success in biotech innovation. And that says a lot about the strategies that AstraZeneca will follow in the years ahead.
Veteran biotech exec Jack Talley has stepped into the top job at Actinium Pharmaceuticals, a low-profile developer which has been pursuing a lengthy effort to develop an armed antibody that can be used to fight blood cancers.
Dear readers, we at FierceMarkets would like to introduce you to a new feature, Chutes & Ladders, which we intend to make the industry's best weekly roundup of C-level hires and fires,...
South Africa's Cipla Medpro suspended its CEO and founder, Jerome Smith. The company, which happens to be the country's third-largest drugmaker, is conducting an internal investigation. That much we know.
We'd like to be hiding under the dessert cart when Carl Icahn sits down to dinner with Forest Laboratories CEO Howard Solomon. The rabble-rousing activist investor has spent the last several months throwing knives at Solomon, and Solomon hasn't been shy about wielding his own blades.
It appears that weeks of acerbic attacks against the oversight of the Forest Laboratories board and the rule of its octogenarian CEO Howard Solomon has paid off for investor Carl Icahn, getting him a supporter on the board. How effective a single voice can be in what may be a very hostile work environment is hard to imagine.
Former Pfizer CEO Jeff Kindler has found a second act as a venture capitalist. He has joined Lux Capital as a venture partner, which has different meanings at different VC firms, but in this case calls on him to work with Lux's portfolio companies and to aid the group in picking winners in healthcare.